Therapeutic Potential of Intravenous Phage as Standalone Therapy for Recurrent Drug-Resistant Urinary Tract Infections.

abstract

• Recurrent urinary tract infections (rUTI) are common in kidney transplant recipients (KTR) and are associated with multidrug resistance and increased morbidity/mortality. Novel antibiotic alternatives to reduce UTI recurrence are critically needed. We describe a case of rUTI due to extended spectrum beta lactamase (ESBL) Klebsiella pneumoniae in a KTR that was treated successfully with 4 weeks of adjunctive intravenous bacteriophage therapy alone, without concomitant antibiotics, and with no recurrence in a year of follow-up.

authors

• Gill, Jason

published proceedings

• Antimicrob Agents Chemother

altmetric score

• 12.95

author list (cited authors)

• Le, T., Nang, S. C., Zhao, J., Yu, H. H., Li, J., Gill, J. J., Liu, M., & Aslam, S.

citation count

• 2

complete list of authors

• Le, Tram||Nang, Sue C||Zhao, Jinxin||Yu, Heidi H||Li, Jian||Gill, Jason J||Liu, Mei||Aslam, Saima

publication date

• April 2023

publisher

• American Society for Microbiology  Publisher

published in

• Antimicrobial Agents and Chemotherapy  Journal

keywords

• Anti-Bacterial Agents
• Bacteriophage
• Beta-Lactamases
• Esbl
• Humans
• Kidney Transplant
• Klebsiella Pneumoniae
• Phage
• Retrospective Studies
• Ruti
• Urinary Tract Infections

PubMed Central ID

• 36975787

Digital Object Identifier (DOI)

• 10.1128/aac.00037-23

start page

• e0003723

end page

• e00023

volume

• 67

issue

• 4

URL

• http://dx.doi.org/10.1128/aac.00037-23